FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 370 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Removing senescent immune cells could be the key to preventing some... June 1, 2023 Tailored Psychotherapy Eases Depression in People with Advanced Cancer August 9, 2018 20 years on: how we’ve decreased cancer death rates December 17, 2022 Spending Review 2021: Promising commitments, but a lot of unanswered questions October 27, 2021 Load more HOT NEWS Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... Screening Programme by Primary Colonoscopy or Two Rounds of Two-Stool FIT... Activity of Targeted/Immune Therapy Approach in Patients with Advanced Urothelial Cancer Can Being Exposed to Wildfire Smoke Affect Your Cancer Risk?
